Join the Oncology Voice Network. Join for Free
Bringing the Patient Voice into Company-Sponsored Publications: The Med Comms Perspective
patient participation in scientific publishing medical communications and patient engagement roles of patients in research communicating with patient advocates patient education in research patient engagement podcast scientific publishing process

Bringing the Patient Voice into Company-Sponsored Publications: The Med Comms Perspective


Share This Article


Summary

Continuing our look at increasing patient participation in the scientific publication process, this episode of InformED will look at the process from a medical communications perspective. Our guests discuss questions to think through during the planning stages including: the different roles that patients can take, how to best communicate with patients and patient advocates, and education they may need to fully engage in the process.

Guest host Kelly Soldavin, Senior Editor at Taylor & Francis Group is joined by Jacqui Oliver, Patient Partnership Director, Scientific at Envision Pharma Group and Sarah Griffiths, Communications Director, Patient Engagement at Oxford PharmaGenesis to for this second episode in a series of patient engagement in scientific publishing podcasts.

Click for Source
patient participation in scientific publishing, medical communications and patient engagement, roles of patients in research, communicating with patient advocates, patient education in research, patient engagement podcast, scientific publishing process

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements
OVN Avatar Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr

The Oncology Data Network (ODN): Methodology, Challenges, and Achievements

Article
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
OVN Avatar Alyson Haslam, PhD; Vinay Prasad, MD, MPH

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

Article
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
OVN Avatar Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Article
Expert perspectives live from ASCO® 2025
Partner Avatar iNIZIO

Expert perspectives live from ASCO® 2025

Article
Where Did My Interview Go Wrong?
Partner Avatar Tom Caravela

Where Did My Interview Go Wrong?

Article
Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities
OVN Avatar Nidal Al-Huniti, Yan Feng, Jingyu (Jerry) Yu, Zheng Lu, Mario Nagase, Diansong Zhou, Jennifer Sheng

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

Explore OVN